Canlyniadau Chwilio - Steven D. Nathan

Mireinio'r Canlyniadau
  1. 1
    IPF clinical trial design and endpoints

    IPF clinical trial design and endpoints gan Steven D. Nathan, Keith C. Meyer

    Cyhoeddwyd 2014
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation

    Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation gan Oksana A. Shlobin, Steven D. Nathan

    Cyhoeddwyd 2012
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis

    Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis gan Abhimanyu Chandel, Jean Pastré, S. Valéry, Christopher S. King, Steven D. Nathan

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics

    Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics gan Andrew F. Shorr, Donald L. Helman, D. B. Davies, Steven D. Nathan

    Cyhoeddwyd 2005
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

    Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis gan William M. Reichmann, Yanni Yu, Dendy Macaulay, Eric Q. Wu, Steven D. Nathan

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant

    Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant gan Andrew F. Shorr, Jennifer L. Wainright, Cindy Cors, Christopher J. Lettieri, Steven D. Nathan

    Cyhoeddwyd 2007
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis

    The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis gan Christopher J. Lettieri, Steven D. Nathan, Robert Browning, Scott D. Barnett, Shahzad Ahmad, Andrew F. Shorr

    Cyhoeddwyd 2006
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    SERIAL MEASURES OF PULMONARY ARTERY PRESSURES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

    SERIAL MEASURES OF PULMONARY ARTERY PRESSURES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS gan Steven D. Nathan, Shahzad Ahmad, James P. Koch, Scott D. Barnett, Niv Ad, Nelson A. Burton

    Cyhoeddwyd 2005
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Heart rate recovery after six‐minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis

    Heart rate recovery after six‐minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis gan Jeffrey J. Swigris, Amy L. Olson, Oksana A. Shlobin, Shahzad Ahmad, Kevin K. Brown, Steven D. Nathan

    Cyhoeddwyd 2010
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    The 6-min walk test as a primary end-point in interstitial lung disease

    The 6-min walk test as a primary end-point in interstitial lung disease gan Sergio Harari, Athol U. Wells, Wim Wuyts, Steven D. Nathan, Klaus-Uwe Kirchgaessler, Monica Bengus, Jürgen Behr

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis

    Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis gan Stephanie Shin, Christopher S. King, Nitin Puri, Oksana A. Shlobin, Anne Brown, Shahzad Ahmad, Nargues Weir, Steven D. Nathan

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis

    Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis gan Mark Fisher, Steven D. Nathan, Christian Hill, J.D. Marshall, F. Dejonckheere, Per-Olof Thuresson, Toby M. Maher

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views

    Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views gan Toby M. Maher, Jeffrey J. Swigris, Michael Kreuter, Marlies Wijsenbeek, Nicola Cassidy, Lucy Ireland, Judit Axmann, Steven D. Nathan

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease

    Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease gan Ho Cheol Kim, Abhimanyu Chandel, Christopher S. King, Min Jee Kim, Malek Shawabkeh, Ambalavanan Arunachalam, Rade Tomic, Steven D. Nathan

    Cyhoeddwyd 2025
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis

    Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis gan Steven D. Nathan, Ashwin Basavaraj, Cristina Reichner, Oksana A. Shlobin, Shahzad Ahmad, Joseph Kiernan, Nelson A. Burton, Scott D. Barnett

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Lung Transplantation for Patients With COVID-19

    Lung Transplantation for Patients With COVID-19 gan Christopher S. King, Hannah Mannem, Jasleen Kukreja, Shambhu Aryal, Daniel Tang, Jonathan P. Singer, Ankit Bharat, Jürgen Behr, Steven D. Nathan

    Cyhoeddwyd 2021
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD

    The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD gan Martin Kolb, Stylianos E. Orfanos, Christopher Lambers, Kevin R. Flaherty, Alison Masters, Lisa Lancaster, Adam M. Silverstein, Steven D. Nathan

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD

    Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD gan Steven D. Nathan, Abhimanyu Chandel, Ya Wang, Jiawei Xu, Lixin Shao, Timothy R. Watkins, Jack Diviney, Christopher S. King, Ling Han

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

    Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Inn... gan Oksana A. Shlobin, Eric Shen, Stephen J. Wort, Lucilla Piccari, John Scandurra, Paul M. Hassoun, Sylvia Nikkho, Steven D. Nathan

    Cyhoeddwyd 2024
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts

    Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts gan Varvara Kirillov, Jonathan T. Siler, Mahalakshmi Ramadass, Lingyin Ge, James E. Davis, Geraldine M. Grant, Steven D. Nathan, Gábor Járai, Glenda Trujillo

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: